| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| Zinlirvimab | 10-1074; 10-1074-LS; GS-2872 | Phase 2 Clinical | The Rockefeller University | HIV Infections; Acquired Immunodeficiency Syndrome | Details |
| PGT121.414.LS | VRC-HIVMAB0107-00-AB | Phase 2 Clinical | National Institute Of Allergy And Infectious Diseases (Niaid) | HIV Infections | Details |
| PGT-121 | PGT-121 | Phase 2 Clinical | International Aids Vaccine Initiative, Theraclone Sciences Inc, The Scripps Research Institute Inc, The Ragon Institute Of Mgh, Mit And Harvard | HIV Infections; Acquired Immunodeficiency Syndrome; Retroviridae Infections; Sexually Transmitted Diseases, Viral | Details |
| Teropavimab | 3BNC117-LS-J; 3BNC117-LS; 3BNC117; GS-5423 | Phase 2 Clinical | The Rockefeller University | HIV Infections; Acquired Immunodeficiency Syndrome | Details |
| Microbicide monoclonal antibody triple combination (Polymun Scientific Immunobiologische Forschung) | Phase 1 Clinical | Polymun Scientific Gmbh | HIV Infections | Details | |
| PDPHV-201401 | PDPHV-201401 | Phase 1 Clinical | National Institute Of Allergy And Infectious Diseases (Niaid) | HIV Infections | Details |
| Elipovimab | GS-9722 | Phase 1 Clinical | Gilead Inc | HIV Infections | Details |
| VRC-HIVAAV070-00-GT | AAV8-VRC07 | Phase 1 Clinical | National Institute Of Allergy And Infectious Diseases (Niaid) | HIV Infections | Details |
| Microbicide Monoclonal Antibody Triple Combination (Polymun) | Phase 1 Clinical | HIV Infections | Details | ||
| env (A, B, C, A/E)/gag DNA Vaccine(NIAID) | PD-201401 | Phase 1 Clinical | National Institute Of Allergy And Infectious Diseases (Niaid) | HIV Infections | Details |
| Vrc-Hivmab0121-00-Ab | CAP256J3LS | Phase 1 Clinical | National Institute Of Allergy And Infectious Diseases (Niaid) | HIV Infections | Details |
| FB-1002(Frontier Biotechnologies) | FB-1002(前沿生物) | Phase 1 Clinical | Frontier Biotechnologies Inc, Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences | Coronavirus Disease 2019 (COVID-19) | Details |
| DS-003 | DS-003; BMS-793 | Phase 1 Clinical | Bristol-Myers Squibb Company | HIV Infections; Neoplasms | Details |
| A-1801 | A-1801 | Clinical | Wuhan BioRaid Biotechnology Co Ltd | HIV Infections | Details |
| English Name | Research Code | Highest Development Stage | Company | Earliest Brand Name | Earliest Approval Country | Earliest Indication | Earliest Approval Company | Earliest Approval Date | Indication | Clinical Trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Radha-108 | Approved | Biomix Network | Receptol | HIV Infections | Details | |||||
| Fostemsavir Tromethamine | BMS-663068; 97IQ273H4L (UNII code); GSK 3684934; BMS-663068-03; GSK-3684934A; BMS 626529 prodrug | Approved | Bristol-Myers Squibb Company | Rukobia | United States | HIV Infections | Viiv Healthcare Co | 2020-07-02 | HIV Infections | Details |